ArticleScientific reports2026
A nutritional risk index-based nomogram for predicting prognosis and identifying induction chemotherapy beneficiaries in nasopharyngeal carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic significance of immune-inflammatory and nutritional indicators in locoregionally advanced nasopharyngeal carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study was designed to assess the prognostic significance of nutritional risk index (NRI) in nasopharyngeal carcinoma (NPC) patients. In this dual-center study, 1,174 patients were enrolled. Kaplan-Meier analysis assessed the association between NRI and prognosis. Independent prognostic factors for nomogram construction were identified using multivariate Cox regression analysis. The predictive nomogram underwent assessment through decision curve analysis (DCA) and calibration curves. The median NRI value was 112.11. Patients with high NRI (≥ 112.11) demonstrated significantly better survival outcomes than those with low NRI (< 112.11) in both cohorts. Multivariate analysis identified that NRI (≥ 112.11 vs. < 112.11) was an independent prognostic factor for distant metastasis-free survival in the training cohort, and for overall survival (OS) and locoregional relapse-free survival in the validation cohort. The constructed nomogram showed strong discriminatory ability (C-index: 0.715 for training; 0.678 for validation) and good calibration. DCA indicated superior clinical net benefit compared to default strategies. Risk stratification revealed that low-risk patients achieved significantly higher 3-year OS (97.8% vs. 81.1%, P < 0.001) and progression-free survival (PFS, 93.0% vs. 69.3%, P < 0.001) than high-risk patients. Within the high-risk group, the induction chemotherapy (IC) plus radiotherapy (RT)/concurrent chemoradiotherapy (CCRT) regimen significantly improved OS and PFS compared to RT/CCRT alone. Among low-risk patients, the two regimens yielded comparable outcomes. The NRI serves as a reliable prognostic indicator for NPC patients. The proposed nomogram enables personalized risk stratification and offers reference for individual treatment regimen selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.